Science Headlines

  • China births drop 3.5 percent in 2017 - China Daily

    SHANGHAI (Reuters) - Births in mainland China fell by 3.5 percent to 17.23 million last year, the China Daily reported on Friday, citing figures from the country's statistics bureau.

  • Slick driving on icy roads after deadly storm across U.S. South

    ATLANTA (Reuters) - Commuters in the U.S. South endured frigid temperatures and slick driving conditions on Thursday after a storm dumped heavy snow across the region, whipped up winds that snapped power lines and led to at least a dozen deaths.

  • Home security company ADT Inc's IPO priced at $14 per share

    (Reuters) - ADT Inc, a provider of security monitoring services, said on Thursday that its initial public offering was priced at $14 per share, below the expected range of $17 to $19.

  • Amazon's review of Toronto could escalate tension with Trump

    TORONTO (Reuters) - Amazon.com Inc's inclusion of Canada's largest city on a list of 20 finalists for a massive new campus could escalate tensions between the tech giant and U.S. President Donald Trump.

  • At AstraZeneca, fewer drug projects bring big productivity jump

    LONDON (Reuters) - A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca , based on one key measure of success. The analysis published on Friday comes at a time of soul-searching among large pharmaceutical companies as they compete with smaller biotech firms, which are getting new drugs to market more efficiently. The turnaround evident this decade at AstraZeneca follows a shrinking of its global research and development organization and a revision of R&D strategy in 2011, a year before the arrival of current chief executive Pascal Soriot. Soriot has since continued the shift to a deeper and narrower focus on priority therapeutic areas, notably cancer. "All these improvements have happened with less people, less sites and less money," Mene Pangalos, who leads AstraZeneca's Innovative Medicines and Early Development unit, told Reuters. Previously, AstraZeneca was a laggard in the pharmaceutical industry with a dismal track record in launching new medicines and a rapidly eroding base business, due to expiring patents on its older medicines. Its average success for getting a drug from the discovery phase through to successful completion of final-stage Phase III clinical trials was at an all-time low of 4 percent in 2005-10, below the industry average of 6 percent. But in the five years from 2012 to 2016, this jumped to 19 percent, while the industry average, according to consultancy CMR International, was little changed. AstraZeneca scientists published the latest findings in the journal Nature Reviews Drug Discovery. Significantly, there was a marked drop in the number of projects started at the discovery stage, with the total falling to just 76 in 2012-16 from 287 in 2005-10. "We're working on far fewer programs and the probability of success on those programs is going up," Pangalos said. "Going from 4 percent to nearly 20 percent is something we are all very happy with but I still want us to do better ... we're still failing 80 percent of the time."

  • At AstraZeneca, fewer drug projects bring big productivity jump

    LONDON, Jan 19 (Reuters) - A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca, based on one key measure of success.

  • Apple, Alphabet employee buses damaged by vandals during commute

    SAN FRANCISCO (Reuters) - Vandals damaged Apple Inc and Alphabet Inc charter buses carrying employees to and from work in California's Silicon Valley in recent days, police said on Thursday.

  • Trump Organization money laundering alleged in Fusion GPS testimony: House Democrat

    WASHINGTON (Reuters) - Transcripts of testimony given by Fusion GPS co-founder Glenn Simpson to the U.S. House Intelligence Committee includes allegations the Trump Organization may have engaged in money laundering, the panel's top Democrat said in a statement on Thursday.

  • FDA plans more restrictive policy for bulk drug compounding

    (Reuters) - The head of the U.S. Food and Drug Administration on Thursday said it is preparing a new, more restrictive policy targeting what drugs compounding pharmacies can produce that do not go through the agency's approval process.

  • U.S. government to shield health workers under 'religious freedom'

    WASHINGTON (Reuters) - The U.S. government is seeking to further protect the "conscience and religious freedom" of health workers whose beliefs prevent them from carrying out abortions and other procedures, in an effort likely to please conservative Christian activists and other supporters of President Donald Trump.

  • More Science Headlines»

News, Photo and Web Search